Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
This website uses cookies for analytics and functionality purposes. To change your cookie settings or find out more, click here.
If you continue browsing our website, you accept these cookies.
